Microvascular blood flow and stasis in transgenic sickle mice: Utility of a dorsal skin fold chamber for intravital microscopy

American Journal of Hematology

Volumn 77, Issue 2, 2004, Pages 117-125

  Kalambur, Venkatasubramaniam S ^a   Mahaseth, Hemchandra ^b   Bischof, John C ^a   Kielbik, Miroslaw C ^b   Welch, Thomas E ^b   Vilbäck, Åsa ^b   Swanlund, David J ^a   Hebbel, Robert P ^b,c   Belcher, John D ^b,c   Vercellotti, Gregory M ^b,c  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Blood flow; Intravital microscopy; Sickle cell disease; Skin fold chambers; Stasis; Vaso occlusion

Indexed keywords

ALPHA GLOBIN; BETA GLOBIN; BETA S ANTILLES GLOBIN; BETA S GLOBIN; UNCLASSIFIED DRUG;

AMBIENT AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HEMOSTASIS; HYPOXIA; IMPLANTATION; INFLAMMATION; INTRAVITAL MICROSCOPY; LEUKOCYTE ADHERENCE; MICROSCOPY; MICROVASCULARIZATION; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REOXYGENATION; SHEAR FLOW; SICKLE CELL ANEMIA; SKINFOLD; TRANSGENIC MOUSE; VENULE;

ANEMIA, SICKLE CELL; ANIMALS; BLOOD CELL COUNT; CELL ADHESION; FEMALE; HEMATOCRIT; LEUKOCYTE ROLLING; LEUKOCYTES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROCIRCULATION; MICROSCOPY; REPERFUSION INJURY; RETICULOCYTES; SKIN;

EID: 4644226872     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20143     Document Type: Article

References (49)

1. Embury SH, Hebbel RP, Steinberg MH, Mohandas N. Pathogenesis of vasoocclusion. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, editors. Sickle cell disease: basic principles and clinical practice. New York: Raven Press; 1994. Vol 21, p 311-326.
2. Pauling L, Itano HA, Singer SJ. Sickle cell anemia, a molecular disease. Science 1949;100:543-548.
3. Bunn FH. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-769.
4. Kaul DK, Hebbel RP. Hypoxia/re-oxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 2000;106:411-420.
5. Osarogiagbon UR, Choong S, Belcher JD, Vercellotti GM, Paller MS, Hebbel RP. Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000;96:314-320.
6. Buchanan GR, Bowman WP, Smith SJ. Recurrent cerebral ischemia during hypertransfusion therapy in sickle cell anemia. J Pediatr 1983;103:921-923.
7. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84:643-649.
8. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997;89:1787-1792.
9. Amogu AU. Leucocyte counts in children with sickle cell anemia usefulness of stable state values during infections. West Afr J Med 2000;19:55-58.
10. Hedo CC, Aken'ova YA, Okpala IE, Durojaiye AO, Salimonu LS. Acute phase reactants and severity of homozygous sickle cell disease. J Intern Med 1993;233:467-470.
11. Singhal A, Doherty JF, Raynes JG, et al. Is there an acute-phase reactant response in steady-state sickle cell disease? Lancet 1993;341:651-653.
12. Stuart J, Stone PC, Akinola NO, Gallimore JR, Pepys MB. Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. J Clin Pathol 1994;47:166-169.
13. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000;96:2451-2459.
14. Francis RB Jr, Haywood LJ. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 1992;84:611-615.
15. Malave I, Perdomo Y, Escalona E, et al. Levels of tumor necrosis factor/cachetin (TNF alpha) in sera from patients with sickle cell disease. Acta Haematol 1993;90:172-176.
16. Croizat H. Circulating cytokines in sickle cell patients during steady state. Br J Haematol 1994;87:592-597.
17. Kuvibidila S, Gardner R, Ode D, Yu L, Lane G, Warrier RP. Tumor necrosis factor alpha in children with sickle cell disease in stable condition. J Natl Med Assoc 1997;89:609-615.
18. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol 2002;24:81-88.
19. Hofstra TC, Kalra VK, Meiselman HJ, Coates TD. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood 1996;87:4440-4447.
20. Fadlon E, Vordermeier S, Pearson TC, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998;91:266-274.
21. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. Neutrophil activation in sickle cell disease. J Leukoc Biol 1999;66:411-415.
22. Kenny MW, George AJ, Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol 1980;33:622-625.
23. Westwick J, Watson-Williams EJ, Krishnamurthi S, et al. Platelet activation during steady state sickle cell disease. J Med 1983;14:17-36.
24. Beurling-Harbury C, Schade SG. Platelet activation during pain crisis in sickle cell anemia patients. Am J Hematol 1989;31:237-241.
25. Papadimitriou CA, Travlou A, Kalos A, Douratsos D, Lali P. Study of platelet function in patients with sickle cell anemia during steady state and vaso-occlusive crisis. Acta Haematol 1993;89:180-183.
26. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 1997;129:507-516.
27. Wun T, Paglieroni T, Field CL, et al. Platelet-erythrocyte adhesion in sickle cell disease. J Invest Med 1999;47:121-127.
28. Inwald DP, Kirkham FJ, Peters MJ, et al. Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br J Haematol 2000;111:474-481.
29. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997;337:1584-1590.
30. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998;101:1899-1904.
31. Kaul DK, Fabry ME, Costantini F, Rubin EM, Nagel RL. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995;96:2845-2853.
32. Embury SH, Mohandas N, Paszty C, Cooper P, Cheung AT. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. J Clin Invest 1999;103:915-920.
33. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA 2002;99:3047-3051.
34. Fabry ME, Costantini F, Pachnis A, et al. High expression of human beta S- and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci USA 1992;89:12150-12159.
35. Rubin EM, Witkowska HE, Sprangler E, et al. Hypoxia-induced in vivo sickling of transgenic mouse red cells. J Clin Invest 1991;87:639-647.
36. Fabry ME, Sengupta A, Suzuka SM, et al. A second-generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. Blood 1995;86:2419-2428.
37. Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood 2003;101:3953-3959.
38. Papenfuss HD, Gross JF, Intaglietta M, Tresse FA. A transparent access chamber for the rat dorsal skin fold. Microvasc Res 1979;18:311-318.
39. Fabry ME, Nagel RL, Pachnis A, Suzuka SM, Costantini F. High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci USA. 1992;89:12150-12154.
40. Burlingame RW, Volzer MA, Harris J, Du Clos TW. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol 1996;156:4783-4788.
41. Hogan RD, Morris RF, McMurray SK. A digital video image splitting device for microvascular measurements. Microvasc Res 1984;27:128-132.
42. Borders JL, Granger HJ. An optical Doppler velocimeter. Microvasc Res 1984;27:117-127.
43. Davis MJ. Determination of volumetric flow in capillary tubes using an optical Doppler velocimeter. Microvasc Res 1987;34:223-230.
44. Baatz H, Steinbauer M, Harris AG, Krombach F. Kinetics of white blood cell staining by intravascular administration of rhodamine 6G. Int J Microcirc Clin Exp 1995;15:85-91.
45. Zweifach BW, Lipowsky HH. Quantitative studies of microcirculatory structure and function. III. Microvascular hemodynamics of cat mesentery and rabbit omentum. Circ Res 1977;41(3):380-390.
46. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003;107:271-278.
47. Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. WBC rolling flux and adhesion were significantly higher in the venules of sickle mice compared to those in normal mice at both ambient air baseline (P < 0.01) and after hypoxia-reoxygenation (P < 0.001). Blood 1989;74:1403-1408.
48. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997;278:876-878.
49. Fabry ME, Suzuka SM, Weinberg RS, et al. Second generation of knockout sickle mice: the effect of HbF. Blood 2001;97:410-418.